



## **IMAGION BIOSYSTEMS LIMITED**

(ASX: IBX)

7 October 2020

### **Imagion announces HREC approval for Phase I study**

MELBOURNE — Imagion Biosystems (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report that it has received approval from the Human Research Ethics Committee (HREC) for the MagSense™ HER2 Phase I study for metastatic breast cancer. With the study now approved the Company can proceed with finalising contracts with individual study sites.

Additionally, the Company reports that manufacturing of the MagSense™ HER2 nanoparticle formulation for the study remains on track, having successfully completed bulk batch production. The company expects to complete the final step of Good Manufacturing Practice (GMP) compliant packaging of the material on time to support the start of the study.

Imagion Biosystems Executive Chairman Bob Proulx said, “We are very pleased with our progress and will now be working diligently with our planned study sites to commence the study this calendar quarter as we have previously advised.”

**-ENDS**

#### **About Imagion Biosystems**

Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

For further information please visit [www.imagionbiosystems.com](http://www.imagionbiosystems.com)

#### **Authorisation & Additional information**

This announcement was authorised by the Disclosure Committee of Imagion Biosystems Limited.

#### **U.S. Media Contact:**

Matthew Wygant  
[matthew@biotechwriting.com](mailto:matthew@biotechwriting.com)  
+1-408-905-7630

#### **Australian Media & Investor Relations:**

Kyahn Williamson, WE Communications  
[We-AUImagionBiosystems@we-worldwide.com](mailto:We-AUImagionBiosystems@we-worldwide.com)  
+61 (0) 401018828